Cancer Vaccine and Pharmacological Tumor Microenvironment Modification Trial for Canine Metastatic Osteosarcoma

Patient Disease:

Canine Osteosarcoma with Metastasis to the Lungs 

Study Name:

Cancer Vaccine and Pharmacological Tumor Microenvironment Modification Trial for Canine Metastatic Osteosarcoma 

Purpose of the study:

  • To evaluate an osteosarcoma tumor lysate vaccine in combination with losartan and propranolol in dogs with metastatic osteosarcoma 

Primary Eligibility Criteria:

  • Dogs that have had surgery to remove their primary tumor and a confirmed diagnosis of osteosarcoma with measureable metastatic disease in the lungs on chest X-rays  

  • Adequate blood work

  • Two-week washout from chemotherapy or radiation therapy; no concurrent treatment with any immunosuppressive drugs  

  • No pre-existing allergic airway disease or a significantly low heart rate 

Study Protocol:

  • The tumor vaccine will be given every 2 weeks for six treatments and then monthly for up to one year.

  • Dogs will also be treated with oral losartan and propranolol to be given twice daily.

  • Rechecks will be required every 2 weeks following the start of treatment until the vaccine therapy is completed, and every 4 weeks thereafter if tumors are stable or better 

Owner Responsibilities:

  • You are responsible for the initial testing to determine study eligibility and any other tests recommended by your pet’s oncologist

  • You are expected to make and keep all appointments associated with the study

  • You must be comfortable administering oral medications at home 

Financial Incentives:

  • The cancer vaccine and oral immune therapy drugs, losartan and propranolol, will be provided at no cost for the first 6 months of treatment. 

  • All recheck appointment charges during the initial 6 months of the study will be covered by the study, including exam fees, blood work, and blood pressure monitoring. 

  • The study will also cover the cost of the recheck chest x-rays performed monthly for the first 6 months to assess your pet’s response to therapy. 

  • Your pet is eligible to receive the vaccine at no cost for up to one year, but after the initial 6 months of the study, you are responsible for all other costs related to study participation 


If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.